海南合瑞首仿布地奈德肠溶胶囊获批，云顶新耀独占被打破，IgA肾病治疗市场竞争格局重塑

Ofweek光电信息网2025-12-24

12月22日，据NMPA官网显示，海南合瑞制药提交的4类仿制药布地奈德肠溶胶囊获批上市，斩获国内首仿，打破云顶新耀在igAN对因治疗市场的独占局面，重塑该领域竞争格局。截图来源：NMPA布地奈德肠溶胶囊是一款布地奈德的创新口服靶向迟释制剂，用于治疗具有进展风险的原发性IgA肾病成人患者。作为全球首个IgA肾病的对因治疗药物，布地奈德肠溶胶囊不仅填补了国内从疾病源头治疗IgA肾病的空白，更为患者提供...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2594406988?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-24 16:07","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2594406988","market":"hk","top_or_hot":-1,"title":"海南合瑞首仿布地奈德肠溶胶囊获批，云顶新耀独占被打破，IgA肾病治疗市场竞争格局重塑","media":"Ofweek光电信息网","content":"<div>\n<p>12月22日，据NMPA官网显示，海南合瑞制药提交的4类仿制药布地奈德肠溶胶囊获批上市，斩获国内首仿，打破云顶新耀在igAN对因治疗市场的独占局面，重塑该领域竞争格局。截图来源：NMPA布地奈德肠溶胶囊是一款布地奈德的创新口服靶向迟释制剂，用于治疗具有进展风险的原发性IgA肾病成人患者。作为全球首个IgA肾病的对因治疗药物，布地奈德肠溶胶囊不仅填补了国内从疾病源头治疗IgA肾病的空白，更为患者提供...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224161452a47268a7&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>海南合瑞首仿布地奈德肠溶胶囊获批，云顶新耀独占被打破，IgA肾病治疗市场竞争格局重塑</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n海南合瑞首仿布地奈德肠溶胶囊获批，云顶新耀独占被打破，IgA肾病治疗市场竞争格局重塑\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-24 16:07 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224161452a47268a7&s=b><strong>Ofweek光电信息网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>12月22日，据NMPA官网显示，海南合瑞制药提交的4类仿制药布地奈德肠溶胶囊获批上市，斩获国内首仿，打破云顶新耀在igAN对因治疗市场的独占局面，重塑该领域竞争格局。截图来源：NMPA布地奈德肠溶胶囊是一款布地奈德的创新口服靶向迟释制剂，用于治疗具有进展风险的原发性IgA肾病成人患者。作为全球首个IgA肾病的对因治疗药物，布地奈德肠溶胶囊不仅填补了国内从疾病源头治疗IgA肾病的空白，更为患者提供...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224161452a47268a7&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224161452a47268a7&s=b","article_id":"2594406988","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224161452a47268a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2594406988","pubTimestamp":1766563620,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"12月22日，据NMPA官网显示，海南合瑞制药提交的4类仿制药布地奈德肠溶胶囊获批上市，斩获国内首仿，打破云顶新耀在igAN对因治疗市场的独占局面，重塑该领域竞争格局。2025年1月1日起布地奈德肠溶胶囊正式纳入医保报销。3家药企争先布局，海南合瑞拿下首仿目前布地奈德肠溶胶囊仅Everest Medicines进口一家企业获批。布地奈德肠溶胶囊的专利在2029年05月到期，3类专利申明表明在专利到期后仿制药即可上市销售。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","01093":"石药集团","BK1583":"高瓴概念","01952":"云顶新耀","BK1161":"生物科技"},"translate_title":"Hainan Herui's first imitation budesonide enteric-coated capsules were approved, Genting Xinyao's monopoly was broken, and the competitive landscape of the IgA nephropathy treatment market was reshaped","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":0.9,"01952":1.5},"content_text":"12月22日，据NMPA官网显示，海南合瑞制药提交的4类仿制药布地奈德肠溶胶囊获批上市，斩获国内首仿，打破云顶新耀在igAN对因治疗市场的独占局面，重塑该领域竞争格局。截图来源：NMPA布地奈德肠溶胶囊是一款布地奈德的创新口服靶向迟释制剂，用于治疗具有进展风险的原发性IgA肾病成人患者。作为全球首个IgA肾病的对因治疗药物，布地奈德肠溶胶囊不仅填补了国内从疾病源头治疗IgA肾病的空白，更为患者提供了创新的治疗选择。大涨1581%重磅品种，云顶新耀独占鳌头布地奈德肠溶胶囊原研公司为Calliditas，作为重磅药物，2019年，云顶新耀从Calliditas公司引进了该产品在大中华地区和新加坡的商业化权益，2023年11月21日在国内获批上市，商品名为耐赋康，用于治疗具有进展风险的原发性免疫球蛋白A（IgA）肾病成人患者，以降低蛋白尿水平。2025年1月1日起布地奈德肠溶胶囊正式纳入医保报销。截图来源：摩熵医药医保目录数据库耐赋康上市后的7个月为云顶新耀贡献了3.53亿元收入，同比增长1581%，贡献了公司一半的销售额，正处于迅速放量的阶段。据摩熵医药数据库显示，2025年上半年布地奈德相关剂型（含肠溶胶囊）在全国医院销售额超45亿元，其中肠溶胶囊跻身品类前五，进一步验证了其在肾病领域的重磅地位。截图来源：摩熵医药-全终端医院销售数据库在国内市场，云顶新耀作为布地奈德肠溶胶囊在中国大陆地区的独家商业化方，在院内市场独占鳌头，占据100%份额。3家药企争先布局，海南合瑞拿下首仿目前布地奈德肠溶胶囊仅Everest Medicines进口一家企业获批。此次海南合瑞制药顺利获批，并拿下国内首仿，打破云顶新耀在igAN对因治疗市场的独占局面。在仿制药布局中，目前还有齐鲁制药和石药集团中诺药业（石家庄）提交了4类仿制申请，均在审评审批中。截图来源：摩熵医药-中国药品审评数据库此外，布地奈德肠溶胶囊以其创新的作用机制和临床优势已经得到了国内外多个权威治疗指南的推荐。目前该品种还有广东恒健制药、陕西丽彩药业等多家企业正在进行BE试验。布地奈德肠溶胶囊的专利在2029年05月到期，3类专利申明表明在专利到期后仿制药即可上市销售。若专利未获延期，市场推广或为他人做嫁衣。不知云顶新耀是否会调整战略，其此前发布的2030年战略明确要实现营收150亿元。截图来源：摩熵医药-全球上市药品专利数据库截至目前，海南合瑞制药（含子公司）有27款品种获批并过评，其中注射用头孢噻肟钠、富马酸酮替芬口服溶液、布地奈德肠溶胶囊、美沙拉秦肠溶缓释胶囊4款品种为首家过评。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2594406988","isCrawlerRequest":true}